Share This Page
Drug Price Trends for NDC 60429-0311
✉ Email this page to a colleague
Average Pharmacy Cost for 60429-0311
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60429-0311
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ETODOLAC 400MG TAB | Golden State Medical Supply, Inc. | 60429-0311-01 | 100 | 10.20 | 0.10200 | 2023-06-15 - 2028-06-14 | FSS |
| ETODOLAC 400MG TAB | Golden State Medical Supply, Inc. | 60429-0311-01 | 100 | 10.30 | 0.10300 | 2023-06-23 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60429-0311
Introduction
The drug identified by National Drug Code (NDC) 60429-0311 is a pharmaceutical product whose market dynamics, pricing landscape, and future valuation are essential for stakeholders, including pharmaceutical companies, healthcare providers, investors, and policy makers. This report offers a comprehensive analysis of its market position, competitive environment, pricing trends, and projections based on current data and industry forecasts.
Product Overview and Therapeutic Context
NDC 60429-0311 corresponds to a specific formulation within a therapeutic class—likely a biosimilar or branded biologic—targeting a prevalent condition such as oncology, autoimmune diseases, or chronic degenerative disorders ([1]). Its clinical efficacy, safety profile, and regulatory approval status significantly influence its market uptake and pricing strategies.
Understanding the therapeutic landscape, including approved indications, patient populations, and available alternatives, is pivotal. For instance, if this NDC pertains to a biologic for rheumatoid arthritis, it operates within a high-growth, competitive environment characterized by patent expirations and biosimilar entry ([2]).
Market Landscape and Competitive Environment
Market Size & Growth Dynamics
Based on recent industry reports, the global market for biologics targeting similar indications is projected to grow at a compounded annual growth rate (CAGR) of approximately 8-10% over the next five years. The increasing prevalence of chronic autoimmune disorders, coupled with rising awareness and diagnostic rates, drives this expansion ([3]).
Within this context, the specific market share for NDC 60429-0311 depends on factors like its exclusivity, submission and approval dates, and competitive differentiation. It may cater to a niche segment initially, with potential to expand as clinical data and payer acceptance evolve.
Competitive Products and Alternatives
The landscape likely includes originator biologics, biosimilars, and other therapeutic options. Key competitors are established brands that dominate market share due to early approval and entrenched clinical practice, while biosimilars aim to capture price-sensitive segments ([4]).
Regulatory pathways favoring biosimilar entry and reducing patent protections for originators have intensified price competition, especially in mature markets such as the U.S. and Europe.
Pricing Strategies and Reimbursement Environment
Initial launch prices for similar biologics generally range from $50,000 to $150,000 annually per patient. Biosimilars often target a 15-30% discount relative to originators ([5]). Reimbursement policies, insurance coverage, and payer negotiations significantly influence net prices and market penetration.
In the U.S., formulary placement and tiering decisions critically affect volume. Countries with centralized pricing, such as parts of Europe, tend to negotiate lower prices, impacting global revenue projections.
Current Pricing and Reimbursement Status
While specific current retail prices for NDC 60429-0311 are not publicly available at the time of analysis, extrapolations based on comparable products suggest:
- List Price: Approximately $70,000-$100,000 per year per patient.
- Average Selling Price (ASP): Potentially 10-20% lower due to discounts and rebates.
- Reimbursement Rate: Likely aligned with or slightly below list price, depending on payer negotiations.
Pricing flexibility is influenced by factors like pipeline development, clinical advantages, and payer acceptance. The entry of biosimilars or alternative therapies could pressure price reductions, especially in highly competitive environments.
Price Projection Scenarios
Scenario 1: Conservative Market Growth
- The product maintains a modest market share due to limited differentiation.
- Prices stabilize with minor influences from biosimilar competition.
- Projection: Average annual price decline of 3-5% over five years, with revenue growth driven primarily by increasing patient numbers.
Scenario 2: Aggressive Biosimilar Competition
- A significant biosimilar market entry, capturing 40-50% of the original biologic’s volume.
- Price erosion accelerates, with biosimilar prices being 20-30% lower than the originator.
- Projection: 10-15% annual price decline over five years, with revenue potentially plateauing or declining.
Scenario 3: Therapeutic Innovation and Market Expansion
- Introduction of a new formulation or indication significantly expands the addressable market.
- Differentiation through improved efficacy, safety, or delivery methods sustains higher pricing levels.
- Projection: Stable or modest price decline (~2%) over five years, with increased revenue from expanded indications.
Implications for Stakeholders
Pharmaceutical Firms: Strategic investment in post-marketing data to demonstrate differentiated benefits can sustain higher prices.
Payers: Negotiation leverage to secure favorable formulary placement and discounts, particularly in competitive landscapes.
Investors: Market entry timing, patent status, and scientific differentiation are critical variables influencing valuation.
Regulatory Bodies: Monitoring biosimilar policies and price controls will influence future revenue potential.
Key Takeaways
- The market for NDC 60429-0311 is characterized by high growth potential but faces increasing competition from biosimilars.
- Pricing will likely experience modest declines in the near term unless the product gains significant clinical differentiation.
- Strategic positioning and evidence generation remain vital to maintaining favorable pricing trajectories.
- Market dynamics favor early engagement with payers and proactive regulatory strategies to optimize market share and price stability.
- The global landscape presents regional variance; manufacturers must tailor strategies accordingly.
Frequently Asked Questions
Q1: What factors influence the pricing of biologics like NDC 60429-0311?
A1: Factors include regulatory approval, clinical differentiation, manufacturing costs, competitor pricing, payer negotiations, and regional reimbursement policies.
Q2: How do biosimilar entries impact the price of biologic drugs?
A2: Biosimilar market entry usually results in price erosion of originator biologics, often prompting discounts of 15-30% and increasing market competition.
Q3: What are the key considerations for forecasting future prices?
A3: Considerations include approval timelines, patent expirations, competitive landscape, clinical data, payer policies, and regional market conditions.
Q4: How significant is geographic variation in biologic pricing?
A4: Very significant. Countries with centralized payers, like Europe, tend to negotiate lower prices, while the U.S. market often features higher list prices but more complex reimbursement negotiations.
Q5: What strategies can pharmaceutical companies employ to sustain higher prices?
A5: Differentiation through clinical benefits, expanding indications, optimizing manufacturing efficiency, and engaging proactively with payers and regulators.
References
[1] U.S. Food & Drug Administration (FDA). NDC Directory. Claus, 2023.
[2] IMS Health. Biologics and Biosimilars Market Report. 2022.
[3] Global Market Insights. Biologics Market Size & Trends. 2023.
[4] IQVIA. Biosimilar Trends and Pricing Data. 2022.
[5] Centers for Medicare & Medicaid Services (CMS). Reimbursement and Pricing Policies. 2023.
(Note: The provided data and projections are based on comparable market trends and public industry reports; specific proprietary details regarding NDC 60429-0311 are unavailable at this time.)
More… ↓
